Human epidermal growth factor receptor 2 (HER2)-inhibition is an important therapeutic strategy in HER2-amplified gastro-oesophageal cancer (GOC). A significant proportion of GOC patients display HER2 amplification, yet HER2 inhibition in these patients has not displayed the success seen in HER2 amplified breast cancer. Much of the current evidence surrounding HER2 has been obtained from studies in breast cancer, and we are only recently beginning to improve our understanding of HER2-amplified GOC. Whilst there are numerous licensed HER2 inhibitors in breast cancer, trastuzumab remains the only licensed HER2 inhibitor for HER2-amplified GOC. Clinical trials investigating lapatinib, trastuzumab emtansine, pertuzumab and MM-111 in GOC have demonstrated disappointing results and have not yet changed the treatment paradigm. Trastuzumab deruxtecan may hold promise and is currently being investigated in phase Ⅱ trials. HER2 amplified GOC differs from breast cancer due to inherent differences in the HER2 amino-truncation and mutation rate, loss of HER2 expression, alterations in HER2 signalling pathways and differences in insulin-like growth factor-1 receptor and MET expression. Epigenetic alterations involving different microRNA profiles in GOC as compared to breast cancer and intrinsic differences in the immune environment are likely to play a role. The key to effective treatment of HER2 amplified GOC lies in understanding these mechanisms and tailoring HER2 inhibition for GOC patients in order to improve clinical outcomes. Core tip: Human epidermal growth factor receptor 2 (HER2)-inhibition is an important therapeutic strategy in HER2-amplified gastro-oesophageal cancer (GOC). A significant proportion of GOC patients display HER2 amplification, yet HER2 inhibition in these patients has not displayed the success seen in HER2 amplified breast cancer. We evaluate current clinical and laboratory evidence surrounding HER2 inhibition in GOC. Inherent differences in the HER2 receptor, signalling pathways, associated microRNA signature and immune environment may partly explain the disappointing clinical trial outcomes seen in GOC. Only with improved understanding of HER2 inhibition can effective treatment be provided in order to improve clinical outcomes for patients.
INTRODUCTION
Cancer therapy is becoming increasingly personalised and molecularly targeted, using biomarkers to identify pa tients most likely to respond to therapy. Human epidermal growth factor receptor 2 (HER2)amplified cancer is defined as cancer with HER2 protein overexpression ± HER2 gene amplification [1] . It represents a molecularly defined subgroup of malignancy and is known to exist in breast and gastrooesophageal cancers (GOC), among others [1] . Whereas the treatment for HER2-amplified breast cancer patients has been extremely successful, the treatment for GOC has been less so. In this review, we explore the mechanisms by which HER2 amplification contributes to cancer progression and prognosis, me thods of targeting HER2 amplification, mechanisms of resistance to HER2 therapy, strategies to overcome re sistance, biomarkers and future directions.
HER2 RECEPTOR AND ITS INTERACTIONS
HER2, encoded by the ERBB2 oncogene on chromosome 17q21 [2] , is a member of the epidermal growth factor receptor (EGFR) family associated with tumour cell proliferation, apoptosis, adhesion, migration and diffe rentiation [3] . All studies investigating HER2 receptor interactions have been conducted in breast cancer ce lls, and a literature search did not reveal any studies of HER2 receptor interactions conducted specifically in GOC. Given the relatively disappointing results seen in GOC, we suggest it may be worthwhile exploring HER2 receptor interactions specifically in GOC, to investigate whether there are any mechanistic differences in HER2 binding and signalling between breast and GOC.
HER2 RECEPTOR OVEREXPRESSION AND ONCOGENIC MECHANISMS IN BREAST AND GOC
In both breast cancer and GOC, HER2 overexpression occurs in approximately 20% [4, 5] . The Gastric Cancer Ge nome Atlas [part of The Cancer Genome Atlas (TCGA)] recently classified gastric cancer into four subtypes and found that HER2 overexpression occurs only in Epstein Barr virus (EBV)positive tumours, genomicallystable (GS) tumours and tumours with chromosomal instabil ity (CIN) but not in microsatellite unstable (MSIhigh) tumours [6] . Mechanisms by which HER2 overexpression can be oncogenic are complex, with activation of RAS MAPK, cjun and AktmTOR pathways [3] ( Figure 1 ).
HER2 overexpression may lead to formation of HER2 homodimers and ligandindependent downstream sign alling [3] . The majority of studies investigating HER2 overexpression oncogenicity have been conducted in breast cancer, and mechanisms may differ in GOC.
INFLUENCE OF HER2 STATUS ON PROGNOSIS IN BREAST AND GASTRIC

CANCER
In contrast to breast cancer, HER2 overexpression does not impact survival in GOC [2] . Large phase Ⅲ prospective randomised controlled trials such as ToGA [5] , LOGiC [7] and TYTAN [8] demonstrate that patients with HER2 amplifi ed GOC who receive the control arm (chemotherapy alone) have an overall survival (OS) similar to allcomers (Table 1 ) [5, 79] . In the first-line ToGA and LOGiC trials, OS was 11.1 mo and 10.5 mo, respectively, in the control arms [5, 7] , compared to OS in allcomers of 9.9 mo in the Phase Ⅲ REAL2 trial [10] . In the 2 nd line TYTAN trial, OS was 8.9 mo in the control [8, 9] , which compared favourably to OS in allcomers treated with paclitaxel in the control arms of the RAINBOW (OS 7.4 mo) [11] and GOLD trials (OS 6.9 mo) [12] . This crosstrial comparison suggests th at HER2 overexpression does not adversely affect GOC prognosis.
HER2 SCORING CRITERIA, DISCORDANCE AND HETEROGENEITY IN GOC AND BREAST CANCER
The HER2 scoring system in breast cancer was dev eloped prior to the scoring system for GOC and was st andardised in 2007 following an expert panel forum [13] .
The ToGA trial used a new immunohistochemistry (IHC) scoring criteria developed by Hofmann [14] for gastric cancer due to inherent biological differences compared to breast cancer, such as tumour heterogeneity and baso(lateral) membrane staining [5, 14] . Some criteria were the same as breast cancer: HER2 positivity was defi ned as an IHC score of 3+ and/or erbB-2 amplification detected using fluorescent insituhybridisation (FI SH) [5, 14] . Notably, GOC patients with highly amplified HER2 gene experience better response and survival than patients with lower HER2 gene amplification le vels when treated with 1 st line trastuzumab plus che motherapy for metastatic gastric cancer [15] . HER2 expression in primary and metastatic sites demonstrates heterogeneity more frequently in GOC than in breast cancer [16, 17] , and discordance between IHC and FISH results occur more frequently in GOC than in breast cancer [18] . This may explain the limited succe ss of targeted antiHER2 therapy in GOC. If only a small proportion of GOC cells shows HER2 overexpression and if our detection methods are unreliable, GOC ca ncer cells that do not overexpress HER2 will not be effectively targeted with antiHER2 therapy, and we may be failing to treat adequately some patients with 161 WJGO|www.wjgnet.com becoming the standard of care in 1 st line metastatic GOC patients [5] . Updated OS (after a further 1 year of followup) released by the United States Food and Dr ug Administration (FDA) in 2016 showed median OS of 13.1 mo (95%CI: 11.915.1) in the trastuzumab plus chemotherapy arm and 11.7 mo (95%CI: 10.313.0) in the control arm (HR = 0.8, 95%CI: 0.670.97) [21] . Subgroup analysis demonstrated that patients with IHC 3+ HER2 expression experienced the greatest benefit from trastuzumab (294 patients, HR = 0.66, 95%CI: 0.50.87). Patients with IHC 2+ HER2 expression gain ed less benefit from the addition of trastuzumab (160 patients, HR = 0.78, 95%CI: 0.551.10), and patients with IHC 1 or 1+ gained no benefit (133 patients, HR = 1.33, 95%CI: 0.921.92) [21] . Recent data on two different doses of trastuzumab in combination with chemotherapy in GOC found that a higher trastuzumab maintenance dose does not convey additional survival benefit (OS 12.5 mo in the 8 mg/kg + 6 mg/kg group vs 10.6 mo in the 8 mg/kg + 10 mg/kg group) [22] . It remains to be seen whether trastuzumab confers a survival benefit in the neoadjuvant/perioperative/ adjuvant setting in combination with chemotherapy + surgery ± radiotherapy, and several phase 2 trials are underway to address this question (UMIN 000016920, NCT01472029, NCT02250209, Table 2 ) [23, 24] . Perioperative trastuzumab appears to be safe and well tolerated [25] . HER2 overexpression.
THERAPEUTIC AGENTS TARGETING THE
HER2 SIGNALLING PATHWAY
Trastuzumab
The efficacy of trastuzumab (a monoclonal antibody against HER2) in breast cancer in combination with ch emotherapy has been convincingly demonstrated in both metastatic (OS 25.1 mo in patients receiving tras tuzumab + chemotherapy vs 20.3 mo in those receiving chemotherapy alone, Table 1 ) [19] and adjuvant settings [20] . Breast cancer OS is, however, influenced by the greater number of treatment options in the 2 nd line setting and beyond.
In GOC, trastuzumab is the only licensed antiHER2 treatment, following positive results from the ToGA tr ial, an openlabel, international, phase 3, randomised controlled trial evaluating trastuzumab plus platinum fluoropyrimidine chemotherapy for 1stline treatme nt of HER2 positive GOC (Table 1 ) [5] . Median OS was initially reported as 13.8 mo (95%CI: 1216) in patien ts receiving trastuzumab plus chemotherapy vs 11.1 mo (1013) in patients receiving chemotherapy alone (HR = 0.74; 95%CI: 0.600.91; P = 0.0046) [5] . This led to trastuzumab plus platinumfluoropyrimidine ch emotherapy followed by trastuzumab maintenance WJGO|www.wjgnet.com One Phase Ⅱ trial evaluating capecitabine + oxaliplatin with trastuzumab three cycles preoperatively and post operatively followed by 12 mo adjuvant trastuzumab reported an 18 mo DFS of 71% (95%CI: 53%83%), a 24 mo DFS of 60% and a median followup of 24.1 mo (median DFS and OS not reached) [26] . Although a phase Ⅲ trial evaluating radiotherapy + chemothera py ± trastuzumab is underway (NCT01196390, Table   2 ) [24] , it is notable that trastuzumab is not being investigated in phase Ⅲ trials in the perioperative GOC setting. This is likely due to the prohibitive number of patients (approximately 10000) that would require screening in order to recruit adequate numbers of pat ients for a sufficiently powered study, given that HER2 overexpression is around 20% [5] , and a relatively small proportion of patients in Western countries are diagnos WJGO|www.wjgnet.com T-DM1 A combination study of kadcyla (trastuzumab emtansine, T-DM1) and capecitabine in patients with HER2-positive metastatic breast cancer and patients with HER2-positive locally advanced/ metastatic gastric cancer (TRAX-HER2 study) [78] Phase Ⅱ
NCT01702558
Capecitabine + trastuzumab emtansine (T-DM1) vs T-DM1
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Safety ORR DS-8201 Phase 1, two-part, multicenter, non-randomized, open-label, multiple dose first-in-human study of DS-8201A, in subjects with advanced solid malignant tumors [36] Phase Ⅱ
NCT02564900
Trastuzumab deruxtecan (DS8201a) deeffects prior to treatment and may be less able to tolerate lapatinib treatment. Another possible reason for the poor efficacy of lapatinib in GOC is that HER2 and EGFR signalling mechanisms may differ as compared to breast cancer. Lapatinib is currently being investigated in Phase II/III trials in the perioperative setting (STO3 trial, NCT00450203, Table 2 ) [24] and as monotherapy in the advanced setting (NCT02342587, Table 3 ) [24] . Safety data from the STO3 trial was presented at ESMO 2016 and suggested that administration of lapatinib at a dose of 1250 mg/d in combination with ECX chemotherapy (capecitabine 1000 mg/m 2 ) was feasible, although there was increased diarrhoea (21% in ECX + lapatinib group vs 0% in ECX group) and neutropenia (42% in ECX + lapatinib group vs 21% in ECX group), which did not appear to compromise operative management [31] .
T-DM1
Trastuzumab emtansine (TDM1) is an antibodydrug conjugate that combines the HER2targeted properties of trastuzumab with the cytotoxic activity of emtansine, enabling selective delivery of chemotherapy to HER2 overexpressing cells [32] . Although TDM1 demonstrated significant clinical benefit in the EMILIA breast cancer trial in the 2 nd line setting (Table 1 ) [33] , a similar study (GATSBY, Table 1 ) in GOC failed to meet its primary endpoint or any of its secondary endpoints [34, 35] . It is worth noting that nearly half of the patients in the GATSBY trial were from the Asia-Pacific region. These patients are generally fit with a good performance status; and, therefore, it is likely that a significant proportion will have received poststudy treatment [35] . TDM1 monotherapy vs TDM1 + capecitabine is being investigated in combination with capecitabine chemotherapy in GOC in pretreated patie nts (NCT01702558, Table 3 ) and recruitment has been completed [24] .
Trastuzumab deruxtecan
Trastuzumab deruxtecan (DS8201) is an antibodydrug conjugate comprising a humanised antibody against HER2 and a topoisomerase Ⅰ inhibitor "payload" bound together by an enzymecleavable linker [36] . A phase Ⅰ open label dose escalation study recently presented at ASCO [37] demonstrated an overall response rate (ORR) of 46.7% in HER2+ breast cancer patients pretreated with TDM1 and pertuzumab and an ORR of 44.4% in gastric cancer patients pretreated with trastuzumab [37] . This high response rate demonstrates that the "payload" bound to the anti-HER2 antibody can make a significant 165 ed with operable disease [27] . Only a proportion of these patients would have an adequate performance status to enter a clinical trial; therefore, trastuzumab will likely never be investigated in phase Ⅲ trials in the periop erative setting.
In advanced GOC, trastuzumab is being investiga ted in combination with bevacizumab (NCT01359397, Table 3 ), afatinib (NCT01522768, Table 3 ) and via intr aperitoneal delivery (NCT01384253, Table 3 ) [24] .
Lapatinib
Lapatinib is an oral tyrosine kinase inhibitor targeting EGFR and HER2 [7, 28] . In breast cancer, lapatinib dem onstrated significant clinical benefit and is now a st andard line of treatment [19, 29, 30] . In contrast, in GOC, although it showed promise in preclinical trials, lapatinib failed to translate into clinical benefit in both 1 st line (LOGiC) [7] and 2 nd line settings (TYTAN) ( Table 1 ) [9] . The reasons for the disappointing results seen in GOC as compared to breast cancer may be related to lapatinib dosage, toxicities experienced, or different underlying HER2 signalling mechanisms in GOC and breast cancer. When lapatinib was combined with paclitaxel in a 1 st line breast cancer study and 2 nd line GOC study (TYTAN), rates of AEs were broadly similar: 77% of patients in the lapatinib arm experienced diarrhoea in both the breast and TYTAN studies vs 29% of patients in the control arm in the breast study and 22% in the TYTAN study [8, 29] . There was, however, a slightly higher rate of treatment discontinuation seen in GOC patients as compared to breast patients, with AEs resulting in treatment disc ontinuation in 16% in the lapatinib plus paclitaxel group vs 13% in the breast study) [8, 29] . In the 1 st line GOC LOGiC trial (Table 1 ) [7] , there were significantly higher toxicity rates in the lapatinib arm than the control arm, with 94% of patients experiencing adverse events (AEs) and 27% serious AEs (SAEs) in the lapatinib arm vs 88% AEs and 19% SAEs in the control arm. Diarrhoea occurred in 58% of patients receiving lapatinib vs 29% in the control arm, leading to lower relative drug exposure in the lapatinib arm [7] . Again lapatinib treatment resulted in higher rates of treatment discontinuation in GOC than breast cancer patients: 21% of patients in the lapatinib arm of LOGiC required treatment discontinuation vs 13% of breast cancer patients in the 2 nd line breast study receiving lapatinib plus capecitabine [30] . Overall, this su ggests that the chemotherapy backbone with which to combine lapatinib is important, and chemotherapy drugs with overlapping toxicity may result in lower lapatinib dose-intensity and reduced efficacy in GOC. Additionally GOC patients frequently experience gastrointestinal si difference to treatment success. For the first time, similar response rates were seen in both breast and gastric cancers pretreated with HER2 inhibitors, and responses were seen even in low HER2expressing tumours [36] . Re sults of the currently planned phase 2 trials are eagerly awaited (NCT02564900, Table 3 ) [24] , and whether the se response rates can translate into improved overall survival remains to be seen.
Pertuzumab
Pertuzumab is a humanised monoclonal antibody tar geting a different HER2 epitope to trastuzumab [38] , pr eventing formation of HER2HER3 heterodimers [39] . It can be administered concurrently with trastuzumab [40] . In the CLEOPATRA breast cancer study, pertuzumab demonstrated significant clinical benefit when added to trastuzumab plus taxane chemotherapy [40] . Disappo intingly, in advanced GOC, the phase Ⅲ JACOB study of pertuzumab + trastuzumab failed to demonstrate a significant improvement in OS [41] . Pertuzumab is currently being explored in combinati on with trastuzumab and chemotherapy in the perioperat ive GOC setting in INNOVATION (NCT02205047) and PETRARCA trials (NCT02581462) and with the addition of radiotherapy in the TRAP trial (NCT02120911) ( Table  2 ) [24] . Preclinical studies investigating pertuzumab in co mbination with TDM1 in GOC cell lines and xenograft mo dels found this combination caused growth inhibition but no tumour shrinkage [42] . A literature search did not reveal any clinical studies investigating this combination in GOC.
MM-111
MM-111 is a bispecific antibody fusion protein designed by Merrimack to inhibit HER3ligand binding and signalling in HER2amplified tumours by preventing formation of HER2HER3 heterodimers [43, 44] . Preclinical studies show ed promise, leading to phase 1 and phase 2 studies in selected tumour types, including HER2-amplified breast and GOC [43, 44] . However, the phase 2 study investigating MM-111 in HER2-amplified GOC patients was terminated early by the independent data monitoring committee when it was found that the addition of MM111 to chemo therapy + trastuzumab resulted in a significantly poorer PFS and OS [43] . In light of the disappointing results seen in GOC [43] , all further studies investigating MM111 were withdrawn, and Merrimack announced that it does not plan to invest further in MM111.
New HER2 inhibitors
Poziotinib is an oral panHER2 inhibitor whose role in combination with trastuzumab and paclitaxel is curre ntly under investigation in advanced gastric cancer (NCT01746771 , Table 3 ) [24] . Phase 1 studies in GOC are investigating MGAH22 (Margetuximab) (NCT01148849, Table 3 ) [24] , a chimeric antiHER2 monoclonal antibody similar to trastuzumab but engineered for increased bi nding [45] . Medimmune is investigating their HER2 inhibitor, MEDI4276, in a Phase 1 trial (NCT02576548, Table 3) in both breast and gastric cancers [24] . Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER1 (EGFR) and HER2 and is currently being explored in phase 1 trials in GOC (NCT02378389, NCT02500199, Table 3 ) [24] .
MECHANISMS THAT MAY AFFECT HER2
INHIBITION IN GOC
Resistance to HER2 therapy can be one of two types: primary (intrinsic) resistance occurs when there is no res ponse to HER2 inhibitors and secondary (acquired) resi stance occurs when there is an initial response followed by cessation of response [46] . Differentiating between these types of resistance is important, as it dictates the optimal timing of treatment strategies.
Alterations to the HER2 receptor
p95HER2: An aminotruncated form of HER2, known as p95HER2 [46] , lacks the region to which trastuzumab binds and is expressed in 20%37% of breast cancer patients [47] and 60%77% of GOC patients with HER2
amplified disease [48, 49] . This may partly explain the poorer response to trastuzumab in GOC as compared to breast cancer.
HER2 mutation:
Within the TCGA, 15 cases of ERBB2 mutation in GOC were detected using RNA evidence out of 215 nonhypermutated tumours [6] . Evaluation of HER2 mutation across an array of tumour types revealed HER2 mutations in around 5% of gastric cancer patients [50] . Neratinib, a panHER tyrosine kinase inhibitor, is being explored in HER2mutated cancer (NCT01953926, Table  3 ) [24] .
Loss of HER2 expression
A recent study presented at ASCO found that 35% of GOC treated with trastuzumab lost HER2 positivity [51] . Similarly, in breast cancer, loss of HER2 positivity has been reported in patients treated with neoadjuvant tr astuzumab + chemotherapy or chemotherapy alone, and loss of HER2 positivity was associated with an increased risk of disease relapse [52] .
Signalling pathways
PIK3CA/PTEN/PI3K/AKT/mTOR pathway:
The an titumour activity of HER2 inhibitors requires downstream inhibition of PI3K/AKT [46, 53] . BOLERO3 was a randomised, doubleblind, placebocontrolled phase 3 trial in HER2 positive, trastuzumabresistant, advanced previously treated breast cancer patients that explored whether the mTOR inhibitor everolimus might restore sensitivity to trastuzumab [54] . It demonstrated significant improvement in PFS with the addition of everolimus [7 mo (95%CI: 6.748.18) in the everolimus group vs 5.78 mo (5.496.9) in the placebo group] [54] . The randomised phase 3 BO LERO1 trial compared everolimus plus trastuzumab plus paclitaxel to placebo plus trastuzumab plus paclitaxel in order to assess whether addition of everolimus at tr eatment outset might prevent intrinsic resistance: primary endpoint (PFS) was not met [55] . Phase 3 clinical trials have not been conducted spe cifically in HER2 positive GOC patients [49] . The phase 3 GRANITE trial randomised 656 patients with advanced pretreated gastric cancer to either everolimus or ma tching placebo [56] . HER2 status was not an inclusion or exclusion criteria, and we do not know the percentage of HER2 positive patients within this trial. The primary en dpoint (OS) was not met, and everolimus was associated with significant side-effects: 21.5% of patients receiving everolimus required drug discontinuation and 55.4% re quired dose adjustments/interruptions [56] . Such high rates of adverse events are concerning in the palliative setting, where quality of life is important.
IGF-1R expression
Insulinlike growth factor1 receptor (IGF1R) is involved in acquired resistance to HER2 blockade in breast cancer [46, 57] and GOC [58] cells in vitro by forming heterodimers with HER2. Blockade of this heterodimer formation in vitro and in vivo restored sensitivity to HER2 [57] , and combination studies of HER2 blockade in combination with IGF1R in hibitors were more effective than either agent alone [59] . Clinical studies exploring IGF1R inhibitors in combination with HER2 inhibitors in breast cancer patients found no significant difference in PFS (NCT00684983) [49] ; other studies evaluating this strategy were withdrawn, and th ere are no GOC studies [49] .
MET overexpression
Clinical studies of MET inhibitors as monotherapy in HER2 negative breast cancer patients did not meet their primary endpoint [49, 60] . In GOC, a randomized doubleblind phase 3 clinical trial exploring MET inhibition in HER2 negative, MET positive GOC patients found no benefit from the addition of the MET inhibitor onartuzumab to chemotherapy [61] . Phase 2 results for an alternative MET inhibitor, tivatinib, similarly showed no survival advantage [62] . In light of the se disappointing results, it is unlikely MET inhibition will be explored in the clinical setting in HER2overexpressing br east or GOC patients.
HSP90
Combining HER2 and Heat shock protein (HSP90)inh ibition to overcome resistance to HER2 inhibitors showed promise preclinically in cell lines and mouse models in breast and GOC cell lines [63] . However, a phase 2 study in breast cancer has not yet released results [64] , and a phase 2 study in gastric cancer was terminated (NCT01402401) [24] .
MicroRNA
MicroRNAs (miRs) are small noncoding RNAs that contr ol gene expression through messenger RNA degradation and posttranscriptional inhibition [65] . MiRs are tissue specific, and different microRNA signatures may occ ur during resistance to HER2 inhibition in breast and GOC. In HER2 positive breast and gastric cancer cells, miR21 overexpression leads to PTEN downregulation, suppression of trastuzumabinduced apoptosis and increased trastuzumab resistance [66, 67] . MiRNA5423p downregulation promotes trastuzumab resistance in br east cancer via AKT activation [68] . MiR7 functions as a suppressor of the oncogenic isoform of HER2, HER2 Δ 16, and reverses HER2 Δ 16induced trastuzumab resistance in breast cancer [69] . The use of miRs not only as biomarkers but as targets for anticancer therapy may allow new therapeutic miR silencing in the future [70] . Inhibition of certain microRNAs may also enhance the effect of HER2 inhibition [71] .
Immune response
Natural killer (NK) cells are required in order to exert trastuzumab's therapeutic effect [46] . Mice deficient in NK cells show trastuzumab resistance [72] and when numbe rs of innate and adaptive immune cells in the tumour microenvironment increase, there is increased tumour eradication [73] . Trials studying the immune environment in GOC are underway (NCT02318901, NCT01526473, NCT02276300, Table 3 ) [24] .
Biomarkers
Specific-uptake positron emission tomography (PET) scans: Targeted PET scans using radiolabell ed trastuzumab (89ZrTrastuzumab) to demonstrate HER2 uptake can give realtime information on HER2 expression levels, visually displaying the development of resistance with the advantage of being relatively non invasive and, therefore, preferable for patients [74] .
Circulating DNA: Circulating DNA may represent a clinically useful biomarker that reduces the need for invasive biopsies. Plasma DNA digital PCR can detect HER2 status in metastatic breast cancer patients [75] . A systematic review and metaanalysis has suggested th at serum HER2 is a potential surrogate for tissue HER2 status in gastric cancer [76] .
CONCLUSION
Despite numerous HER2 inhibitors being investigated in a number of settings, trastuzumab in advanced dis ease is still the only HER2 inhibitor licensed for clinical use in the treatment of GOC. Even within this setting, the overall survival benefit is far less than that seen in breast cancer. Other HER2 inhibitors that have de monstrated success in breast cancer have failed to reach statistically significant endpoints in GOC clinical trials, and it remains to be seen whether clinical trials currently underway will show improved results. HER2 he terogeneity, aminotruncation loss of HER2 expression and differences in signalling pathways may contribute to the disappointing clinical trial outcomes seen in GOC. Different microRNA signatures and immune en vironments are also likely to play a role. Development of new HER2 inhibition strategies in conjunction with further research into how the role of HER2 differs in GOC as compared to breast cancer is required. Clinical trials utilizing biomarkers such as specific uptake PET scans and circulating DNA may provide early insight in to whether patients are responding to HER2 inhibition. Only with improved understanding of HER2 inhibition in GOC can effective treatment be provided in order to improve clinical outcomes for patients.
